Key result
A review of patents claiming Kv1.5 channel blockers for atrial arrhythmias highlights their chemistry and biological data alongside recent evidence of their in vivo antiarrhythmic effects.
Kv1.5 channel blockers represent a promising target for the development of new, safer, and more efficient atrial-selective antiarrhythmic drugs.
No takes yet. Share an insight, caveat, or question.
May inform atrial-selective antiarrhythmic development; leaves open clinical efficacy and safety in humans.
Brendel et al. (2002) conducted a review in Atrial arrhythmias. Blockers of the Kv1.5 channel was evaluated. A review of patents claiming Kv1.5 channel blockers for atrial arrhythmias highlights their chemistry and biological data alongside recent evidence of their in vivo antiarrhythmic effects.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: